Aclaris Therapeutics ACRS Single Reportable — Cost Of Revenue Excluding Restructuring Expense

Similar metrics at other companies

IOVASingle Reportable — Cost Of Revenue

$42.5M-0.5%

ONTOSingle Reportable — Cost Of Revenue Excluding12

$114.14M-0.3%

TWSTReportable Segment — Restructuring and other costs

$0—

TBPHSingle Reportable — Restructuring And Related Expenses

$3.63M—

ADBEReportable Segment — Cost of Revenue

$669M+18.4%

YELPReportable Segment — Cost of revenue (exclusive of depreciation and amortization and stock-based compensation)

$34.64M+17.0%

Questions, answered.

What is Aclaris Therapeutics's single reportable — cost of revenue excluding restructuring expense?

Aclaris Therapeutics (ACRS) reported single reportable — cost of revenue excluding restructuring expense of $395K in Q1 2026.

How has Aclaris Therapeutics's single reportable — cost of revenue excluding restructuring expense changed year-over-year?

Aclaris Therapeutics's single reportable — cost of revenue excluding restructuring expense decreased by 21.9% year-over-year, from $506K to $395K.

What does single reportable — cost of revenue excluding restructuring expense mean?

Captures the direct costs associated with producing the goods or providing the services that generated the segment's revenue, excluding one-time restructuring charges. This metric is essential for evaluating the direct profitability and operational efficiency of the segment's core activities. Monitoring this helps assess the underlying cost structure of the business unit.